title: Pulmonary squamous cell carcinoma and sorafenib.
abstract: Pulmonary squamous cell carcinomas are not often thought to sensitive to targeted agents, like their cousin the adenocarcinoma of the lung. With appropriate testing of molecular markers, squamous cell carcinomas, like adenocarcinomas of the lung, melanomas, and renal cell carcinomas, may be found to be sensitive to newer, targeted agents.
authors.affiliation: Cancer & Blood Specialists of Nevada 2460 W. Horizon Ridge Pkwy., Henderson, Nevada, 89052.
authors.forename: Russell
authors.initials: R
authors.lastname: Gollard
authors.affiliation: Quest Diagnostics 4230 Burnham Ave., Las Vegas, Nevada, 89119.
authors.forename: Diana
authors.initials: D
authors.lastname: Garcia
authors.affiliation: Cedars-Sinai Comprehensive Cancer Center 8700 Beverly Blvd, Suite AC10, West Hollywood, California, 90048.
authors.forename: Ron
authors.initials: R
authors.lastname: Natale
keywords: BRAF mutants; nonsmall cell lung cancer; squamous cell carcinoma; targeted therapy